MedDataX Logo

Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)

NCT00062582 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2016-11-23

No results posted yet for this study

Summary

The aim of the study is to compare the effect of roflumilast and placebo on the lung function in patients with COPD.

Conditions

  • Chronic Obstructive Pulmonary Disease
  • COPD

Interventions

DRUG

Roflumilast

Sponsors & Collaborators

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • AstraZeneca AstraZeneca · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30

Countries

  • United States
  • Argentina
  • Canada
  • Colombia
  • Mexico
  • Peru

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00062582 on ClinicalTrials.gov